These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 12647642)

  • 1. Gemcitabine therapy in patients with advanced pancreatic cancer.
    Min YJ; Joo KR; Park NH; Yun TK; Nah YW; Nam CW; Park JH
    Korean J Intern Med; 2002 Dec; 17(4):259-62. PubMed ID: 12647642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 13-cis-Retinoic acid in combination with gemcitabine in the treatment of locally advanced and metastatic pancreatic cancer--report of a pilot phase II study.
    Michael A; Hill M; Maraveyas A; Dalgleish A; Lofts F
    Clin Oncol (R Coll Radiol); 2007 Mar; 19(2):150-3. PubMed ID: 17355112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multicenter phase-I/II study using a combination of gemcitabine and docetaxel in metastasized and unresectable, locally advanced pancreatic carcinoma.
    Ridwelski K; Fahlke J; Kuhn R; Hribaschek A; Kettner E; Greiner C; Florschuetz A; Manger T; Wilhelm G; Klein H; Hahnfeld S; Lippert H; Meyer F
    Eur J Surg Oncol; 2006 Apr; 32(3):297-302. PubMed ID: 16414235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of standard-dose and low-dose gemcitabine regimens in pancreatic adenocarcinoma patients: a prospective randomized trial.
    Sakamoto H; Kitano M; Suetomi Y; Takeyama Y; Ohyanagi H; Nakai T; Yasuda C; Kudo M
    J Gastroenterol; 2006 Jan; 41(1):70-6. PubMed ID: 16501860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study.
    Tsavaris N; Kosmas C; Skopelitis H; Gouveris P; Kopterides P; Loukeris D; Sigala F; Zorbala-Sypsa A; Felekouras E; Papalambros E
    Invest New Drugs; 2005 Aug; 23(4):369-75. PubMed ID: 16012797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gemcitabine in advanced pancreatic cancer: a phase II trial.
    Crinò L; Mosconi AM; Calandri C; Corgna E; Porrozzi S; Chiara S; Nobili MT; Tonato M
    Am J Clin Oncol; 2001 Jun; 24(3):296-8. PubMed ID: 11404504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of gemcitabine chemotherapy alone for locally advanced pancreatic carcinoma: JCOG0506.
    Ishii H; Furuse J; Boku N; Okusaka T; Ikeda M; Ohkawa S; Fukutomi A; Hamamoto Y; Nakamura K; Fukuda H;
    Jpn J Clin Oncol; 2010 Jun; 40(6):573-9. PubMed ID: 20185458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gemcitabine and ISIS-2503 for patients with locally advanced or metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II trial.
    Alberts SR; Schroeder M; Erlichman C; Steen PD; Foster NR; Moore DF; Rowland KM; Nair S; Tschetter LK; Fitch TR
    J Clin Oncol; 2004 Dec; 22(24):4944-50. PubMed ID: 15611509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gemcitabine in elderly patients with advanced pancreatic cancer.
    Hentic O; Dreyer C; Rebours V; Zappa M; Lévy P; Raymond E; Ruszniewski P; Hammel P
    World J Gastroenterol; 2011 Aug; 17(30):3497-502. PubMed ID: 21941416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer.
    Bramhall SR; Schulz J; Nemunaitis J; Brown PD; Baillet M; Buckels JA
    Br J Cancer; 2002 Jul; 87(2):161-7. PubMed ID: 12107836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stereotactic body radiotherapy and gemcitabine for locally advanced pancreatic cancer.
    Mahadevan A; Jain S; Goldstein M; Miksad R; Pleskow D; Sawhney M; Brennan D; Callery M; Vollmer C
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):735-42. PubMed ID: 20171803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer.
    Abou-Alfa GK; Letourneau R; Harker G; Modiano M; Hurwitz H; Tchekmedyian NS; Feit K; Ackerman J; De Jager RL; Eckhardt SG; O'Reilly EM
    J Clin Oncol; 2006 Sep; 24(27):4441-7. PubMed ID: 16983112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Second-line therapy for gemcitabine-pretreated advanced or metastatic pancreatic cancer.
    Altwegg R; Ychou M; Guillaumon V; Thezenas S; Senesse P; Flori N; Mazard T; Caillo L; Faure S; Samalin E; Assenat E
    World J Gastroenterol; 2012 Mar; 18(12):1357-64. PubMed ID: 22493549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful adjuvant bi-weekly gemcitabine chemotherapy for pancreatic cancer without impairing patients' quality of life.
    Toyama Y; Yoshida S; Saito R; Kitamura H; Okui N; Miyake R; Ito R; Son K; Usuba T; Nojiri T; Yanaga K
    World J Surg Oncol; 2013 Jan; 11():3. PubMed ID: 23302293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gemcitabine as palliative treatment in patients with unresectable pancreatic cancer previously treated with placement of a covered metal stent. A randomized controlled trial.
    Xinopoulos D; Dimitroulopoulos D; Karanikas I; Fotopoulou A; Oikonomou N; Korkolis D; Kouroumalis E; Antsaklis G; Vassilopoulos P; Paraskevas E
    J BUON; 2008; 13(3):341-7. PubMed ID: 18979547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. S-1 monotherapy as second-line treatment for advanced pancreatic cancer after gemcitabine failure.
    Todaka A; Fukutomi A; Boku N; Onozawa Y; Hironaka S; Yasui H; Yamazaki K; Taku K; Machida N; Sakamoto T; Tomita H
    Jpn J Clin Oncol; 2010 Jun; 40(6):567-72. PubMed ID: 20189975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer.
    Gonçalves A; Gilabert M; François E; Dahan L; Perrier H; Lamy R; Re D; Largillier R; Gasmi M; Tchiknavorian X; Esterni B; Genre D; Moureau-Zabotto L; Giovannini M; Seitz JF; Delpero JR; Turrini O; Viens P; Raoul JL
    Ann Oncol; 2012 Nov; 23(11):2799-2805. PubMed ID: 22771827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study.
    Park SJ; Kim H; Shin K; Hong TH; Suh JH; Lee MA
    BMC Cancer; 2021 Nov; 21(1):1176. PubMed ID: 34732161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gemcitabine treatment in patients with inoperable locally advanced/metastatic pancreatic cancer and prognostic factors.
    Sezgin C; Karabulut B; Uslu R; Sanli UA; Goksel G; Yuzer Y; Goker E
    Scand J Gastroenterol; 2005 Dec; 40(12):1486-92. PubMed ID: 16293561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer.
    Kozuch P; Grossbard ML; Barzdins A; Araneo M; Robin A; Frager D; Homel P; Marino J; DeGregorio P; Bruckner HW
    Oncologist; 2001; 6(6):488-95. PubMed ID: 11743211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.